Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 150 Results

Title
Intervention Indication Therapeutic Area Year Actions
Axicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) – second line Brexucabtagene autoleucel (Tecartus; KTE-X19) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2017 View  |  Download
bb2121 for Relapsed and Refractory Multiple Myeloma Idecabtagene vicleucel (Ide-cel; bb2121) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Belantamab mafodotin for relapsed / refractory multiple myeloma – Fourth line Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2019 View  |  Download
Belantamab mafodotin for treating relapsed or refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Belantamab mafodotin with bortezomib and dexamethasone for previously treated relapsed/refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) , Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated relapsed/refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Belinostat (Beleodaq) with CHOP for treatment of patients with peripheral T‐cell lymphoma, 1st line Belinostat (Beleodaq; PXD101) , CHOP Peripheral T-cell lymphoma (PTCL) Haematological Cancer and Lymphomas 2017 View  |  Download
Blinatumomab (Blincyto) for First Relapsed/Refractory, B-precursor, Acute Lymphoblastic Leukaemia, in Children and Adolescents Blinatumomab (Blincyto) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2017 View  |  Download
Blinatumomab with chemotherapy for frontline consolidation treatment of Philadelphia chromosome negative, measurable residual disease negative, B-lineage acute lymphoblastic leukaemia Blinatumomab (Blincyto) , Chemotherapy Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2024 View  |  Download
Bosutinib (Bosulif) for Philadelphia positive chronic myeloid leukaemia – first line Bosutinib (Bosulif; PF-05208763; bosutinib monohydrate) Chronic myeloid leukaemia (CML) Haematological Cancer and Lymphomas 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications